p-Tau217

Where the papers sit

12 papers from the last 6 months study p-Tau217 directly · updated from PubMed 12 Oct 2026

• Plasma Biomarker Validation

  Clinical use is moving toward plasma p-tau217 as a practical marker of amyloid pathology and treatment eligibility. Lumipulse performance is being tested against other platforms, with attention to analytical robustness, dynamic range, and agreement with PET and amyloid status. p-tau181, amyloid beta 42, and longitudinal biomarker relationships provide context for interpretation. Discordant p-tau217 results, including across ethnically diverse memory-clinic cohorts, leave cutoffs and discordance management open.

  7 papers · 58.3%

• Cognitive Decline Prediction

  Plasma p-tau217 is being evaluated as a prognostic signal for cognitive impairment and dementia. Studies link baseline levels with subsequent cognitive decline and examine how biomarker trajectories relate to subjective cognitive decline and clinical risk factors. Longitudinal data in Down syndrome extend the question beyond typical memory-clinic populations. The work supports risk stratification, but follow-up duration and generalisability remain limiting.

  3 papers · 25%

• Blood Neurodegeneration Biomarkers

  Blood biomarkers are being used to relate neurodegenerative pathology to cognition and clinical symptoms. GFAP, neurofilament light chain, and tau recur across studies using immunoassays and remote capillary sampling. The evidence spans Alzheimer's disease and temporal lobe epilepsy, linking biomarker levels with cognitive or neurological status. Their clinical relevance and the reliability of minimally invasive sampling remain the main open questions.

  2 papers · 16.7%